36000 at thhe bid is more reflective of the sentiment. JC won't make it to see the light of phase 3 as investors will want a CEO who can be more honest and not with the shady history that this guy has. At this point the chances of this trial being successful are slim since most likely something went wrong. Newbies please do your due diligence personaly without being influenced by the commented in this board. This company is late by a year and there have been many misleading PR's. Do not consider articles from biomedreports given that some of these publications or interviews are very biased. Read the PR's straight from BMOD and match them to today's reality.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.